Literature DB >> 32036455

Guidelines for uveal melanoma: a critical appraisal of systematically identified guidelines using the AGREE II and AGREE-REX instrument.

Theresa Steeb1, Kinan M Hayani2, Paul Förster3, Raffael Liegl3, Frédéric Toussaint1, Max Schlaak2, Carola Berking1, Markus V Heppt4.   

Abstract

PURPOSE: Clinical practice guidelines provide recommendations for the management of diseases. In orphan conditions such as uveal melanoma (UM), guideline developers are challenged to provide practical and useful guidance even in the absence of high-quality evidence. Here, we assessed the methodological quality and identified deficiencies of international guidelines on UM as a base for future guideline development.
METHODS: A systematic search was carried out in guideline databases, Medline and Embase until 27th May 2019 for guidelines on UM published between 2004 and 2019. Five independent reviewers assessed the methodological quality of the identified guidelines using the instruments "Appraisal of Guidelines for Research and Evaluation II" (AGREE II) and AGREE-REX (Recommendation EXcellence). Descriptive analysis was performed and subgroup differences were explored with the Kruskal-Wallis (H) test. The relationship between the individual domains and items of the instruments were examined using Spearman's correlation.
RESULTS: Five guidelines published from 2014 to 2018 by consortia of the United States of America, Canada and the United Kingdom (UK) were included. The highest scores were obtained by the UK guideline fulfilling 48-86% of criteria in AGREE II and 30-60% for AGREE-REX. All guidelines showed deficiencies in the domains "editorial independence", "applicability", and "recommendation". Subgroup differences were identified only for the domain "editorial independence".
CONCLUSION: The UK guideline achieved the highest scores with both instruments and may serve as a basis for future guideline development in UM. The domains "editorial independence", "recommendation", and "applicability" were identified as methodological weaknesses and require particular attention and improvement in future guidelines.

Entities:  

Keywords:  AGREE; Guideline; Ocular melanoma; Orphan disease; Practice guideline; Uveal melanoma

Year:  2020        PMID: 32036455     DOI: 10.1007/s00432-020-03141-w

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  6 in total

1.  Nation-Wide Trends in Incidence-Based Mortality of Patients with Ocular Melanoma in USA: 2000 to 2018.

Authors:  Srijan Valasapalli; Achuta Kumar Guddati
Journal:  Int J Gen Med       Date:  2021-08-05

2.  Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience.

Authors:  Cornelia L A Dewald; Mia-Maria Warnke; Roland Brüning; Martin A Schneider; Peter Wohlmuth; Jan B Hinrichs; Anna Saborowski; Arndt Vogel; Frank K Wacker
Journal:  Cancers (Basel)       Date:  2021-12-27       Impact factor: 6.639

3.  Proteomics analysis: inhibiting the expression of P62 protein by chloroquine combined with dacarbazine can reduce the malignant progression of uveal melanoma.

Authors:  Xifeng Fei; Xiangtong Xie; Ruwei Qin; Anqi Wang; Xuan Meng; Fei Sun; Yifan Zhao; Dongyi Jiang; Hanchun Chen; Qiang Huang; Xiaoyan Ji; Zhimin Wang
Journal:  BMC Cancer       Date:  2022-04-14       Impact factor: 4.430

4.  Quality assessment of clinical practice guidelines on psychological distress of cancer patients using the AGREE II instrument.

Authors:  Ran Hao; Haoyu Jin; Jinfan Zuo; Rumeng Zhao; Jie Hu; Yixin Qi
Journal:  Front Oncol       Date:  2022-08-09       Impact factor: 5.738

5.  A Critical Appraisal of Evidence- and Consensus-Based Guidelines for Actinic Keratosis.

Authors:  Anja Wessely; Theresa Steeb; Franz Heppt; Annkathrin Hornung; Matthias D Kaufmann; Elias A T Koch; Frédéric Toussaint; Michael Erdmann; Carola Berking; Markus V Heppt
Journal:  Curr Oncol       Date:  2021-02-19       Impact factor: 3.677

6.  Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG).

Authors:  Theresa Steeb; Anja Wessely; Max Schlaak; Markus V Heppt; Mareike Alter; Christiane Bayerl; Armin Bender; Guido Bruning; Evelyn Dabrowski; Dirk Debus; Nina Devereux; Edgar Dippel; Konstantin Drexler; Pia Dücker; Reinhard Dummer; Steffen Emmert; Peter Elsner; Alexander Enk; Christoffer Gebhardt; Anja Gesierich; Matthias Goebeler; Sergij Goerdt; Steven Goetze; Ralf Gutzmer; Sebastian Haferkamp; Gesina Hansel; Jessica C Hassel; Lucie Heinzerling; Katharina C Kähler; Kjell M Kaume; Wolfgang Krapf; Nicole Kreuzberg; Percy Lehmann; Elisabeth Livingstone; Harald Löffler; Carmen Loquai; Cornelia Mauch; Johanna Mangana; Friedegund Meier; Markus Meissner; Rose K C Moritz; Lara Valeska Maul; Verena Müller; Peter Mohr; Alexander Navarini; Ahn Van Nguyen; Christiane Pfeiffer; Claudia Pföhler; Christian Posch; Erika Richtig; Rainer Rompel; Michael M Sachse; Stefanie Sauder; Dirk Schadendorf; Kerstin Schatton; Hans-Joachim Schulze; Erwin Schultz; Bastian Schilling; Matthias Schmuth; Jan C Simon; Markus Streit; Patrick Terheyden; Alexander Thiem; Thomas Tüting; Julia Welzel; Gerhard Weyandt; Ulrich Wesselmann; Uwe Wollina; Mirjana Ziemer; Lisa Zimmer; Markus Zutt; Carola Berking
Journal:  J Cancer Res Clin Oncol       Date:  2020-11-21       Impact factor: 4.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.